Marion McCourt, Executive Vice President Commercial at Regeneron Pharmaceuticals, Inc., filed a Form 4 on November 3, 2026, disclosing the sale of 1,132 shares of common stock on October 30, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
  • Shares disposed: 1,132 shares of common stock sold on October 30, 2026, at $869.43 per share
  • Transaction code: S (sale), executed pursuant to a Rule 10b5-1(c) plan adopted on February 17, 2026
  • Direct holdings after transaction: 10,871 shares of common stock held directly
  • Indirect holdings: 219 shares held indirectly through a 401(k) Plan

McCourt's October 2026 Common Stock Sale Under 10b5-1 Plan

According to the filing, Marion McCourt, identified as EVP Commercial and an officer of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), disposed of 1,132 shares of Regeneron common stock on October 30, 2026, at a price of $869.43 per share. The transaction is coded "S" in the filing, indicating an open-market sale. The filing notes the box indicating a Rule 10b5-1(c) transaction was checked, and the explanation of responses states that the "Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026."

Following the reported transaction, McCourt directly held 10,871 shares of Regeneron common stock, according to the filing. Additionally, the filing reports 219 shares held indirectly through a 401(k) Plan. No derivative securities transactions were reported in Table II of the form.

The Form 4 was signed by Marion McCourt and filed with the SEC on November 3, 2026, with the date of earliest transaction listed as October 30, 2026. The filing was made as an individual reporting person and is not an amendment to a prior form.

What Was Disclosed

The filing disclosed a single sale of 1,132 shares of Regeneron common stock at $869.43 per share by EVP Commercial Marion McCourt on October 30, 2026, conducted under a pre-established Rule 10b5-1(c) plan, leaving McCourt with 10,871 directly held shares and 219 indirectly held shares.